STING1 and ovarian serous adenocarcinoma: Ghaffari et al. (2018) showed that STING agonists combined with anti-PD-1 antibodies greatly promoted IFN response and MHC class II gene expression, and enhanced the therapeutic effect of carboplatin in a mouse model of highly malignant serous ovarian cancer. Grabosch et al. (2019) demonstrated that cisplatin treatment could modulate the immune environment via activating the STING pathway, and thus enhances tumor immunogenicity and clearance by increasing adaptive immunity related molecules and T-cell infiltration in mouse EOC models.